Clinical trials: HSV-2
HSV-2 Infection, Genital Herpes
The VIBLOK SAfety and perFormancE Trial
Genital herpes has a high prevalence in industrialized as well as developing countries. Genital herpes causes genital ulcers, increases risk for acquiring HIV infection, and may be transmitted mother to child during birth with…
- Trial name
- SAFE (NCT03080961)
- Testing
- VIBLOK barrier cream
- Where
- 3 sites in Netherlands
- Volunteers
- 82 people
- Sponsor
- CLJI Worldwide
HIV/AIDS, HSV-2 Infection
The Impact of VCT and Condom Distribution as HIV Prevention Strategies Among Youth in Kenya
The vast majority of new HIV infections occur in sub-Saharan Africa, where nearly 2 million people become infected with HIV/AIDS every year.
- Trial name
- NCT03868644
- Testing
- Voluntary Counseling and Testing for HIV (VCT), Condoms
- Volunteers
- 10,646 people
- Sponsor
- Abdul Latif Jameel Poverty Action Lab
HSV-2 Infection, HIV Infections
Impact Evaluation of a School-Based Sexuality and HIV Prevention Education Activity in South Africa
The purpose of this study is to evaluate the impact of the new South African Department of Basic Education (DBE) sexuality and HIV education program that uses scripted lesson plans and supporting activities and will be…
- Conditions
- HSV-2 Infection, HIV Infections, Pregnancy Related
- Trial name
- NCT04205721
- Testing
- School-based sexuality and HIV prevention scripted lesson plans
- Where
- South Africa
- Volunteers
- 23,061 people
- Sponsor
- University of North Carolina, Chapel Hill
Hiv, HSV
Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG
The purpose of this Phase I study is to assess the safety, pharmacokinetics, and pharmacodynamics of a combination vaginal insert containing tenofovir alafenamide (TAF) and elvitegravir (EVG).
- Trial name
- NCT03762772
- Testing
- TAF/EVG Vaginal Insert
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- CONRAD
Genital Herpes, HSV-2 Infection
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence.
- Trial name
- NCT03146403
- Testing
- GEN-003, Matrix-M2, 0.9% normal saline
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Genocea Biosciences, Inc.
HIV Infections, HSV-2 Genital Herpes
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013…
- Trial name
- NCT00740584
- Testing
- 3% SPL7013 Gel (VivaGel)
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Starpharma Pty Ltd
HIV/AIDS, HSV-2 Infection
Cash Transfer to Adolescent Girls and Young Women to Reduce Sexual Risk Behavior - an Impact Evaluation
Vulnerability to HIV infection in Adolescent Girls and Young Women (AGYW) is mainly influenced by structural factors which mediate through sexual risk behavior.
- Trial name
- CARE (NCT03597243)
- Testing
- Cash Transfer
- Where
- Tanzania
- Volunteers
- 3,120 people
- Sponsor
- National Institute for Medical Research, Tanzania
HSV Infection, HIV Infection
Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons
The purpose of this study is to determine whether treating HSV-2 with either valacyclovir or acyclovir is more effective in suppressing HIV-1 virus levels in people co-infected with HIV-1 and HSV-2.
- Trial name
- ACV-VAL (NCT01026454)
- Testing
- acyclovir, valacyclovir
- Where
- Kenya
- Volunteers
- 32 people
- Sponsor
- University of Washington
HSV-1, HIV
HSV Oral Reactivation in Children
In the proposed study, the investigators will carry out novel research to evaluate both symptomatic and asymptomatic daily oral herpes simplex virus (HSV) shedding rates and copy number in children with and without HIV.
- Trial name
- NCT01878279
- Testing
- Underlying medical illness
- Where
- Tanzania
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
HIV-1 and HSV-2 Coinfection, HIV Infections
Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon
The study proposed that both clinical and subclinical HSV reactivation is associated with increased HIV shedding from mucosal surfaces, which may increase the infectiousness of HIV-1/HSV-2 coinfected persons.
- Trial name
- NCT00209313
- Testing
- Acyclovir
- Where
- Cameroon
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
HIV, Hepatitis C
Injecting Drug Use Community Intervention Trial
The purpose of this study is to reduce the HIV/HCV incidence among the clients attending community-based methadone maintenance treatment (MMT) , and to prevent the secondary sexual transmission from HIV+ clients to their spouse…
- Conditions
- HIV, Hepatitis C, Syphilis, HSV-2
- Trial name
- NCT01108614
- Testing
- Intervention
- Where
- 5 sites in China
- Volunteers
- 12,000 people
- Sponsor
- National Center for AIDS/STD Control and Prevention, China CDC
HSV-2
A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing.
- Trial name
- NCT00310271
- Testing
- pPJV7630 with pPJV2012 administered by PMED
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- PowderMed
HSV-2
Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing.
- Trial name
- NCT00274300
- Testing
- pPJV7630 administered by PMED
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- PowderMed